Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Summary of Summarized Financial Information for the Company's Segments

Summarized financial information for the Company’s segments is shown in the following tables:

(in thousands)	Three Months Ended March 31,
	2023		2022
Revenue
Patient services	$	50,273	$	35,057
Dispensary	24,240		18,679
Clinical trials & other	1,679		1,425
Consolidated revenue	$	76,192	$	55,161
Direct costs
Patient services	$	42,814	$	27,378
Dispensary	19,145		15,324
Clinical trials & other	134		137
Total segment direct costs	$	62,093	$	42,839
Depreciation expense
Patient services	$	406	$	250
Dispensary	16		—

(in thousands)	Three Months Ended March 31,
	2023		2022
Clinical trials & other	—		47
Total segment depreciation expense	$	422	$	297
Amortization of intangible assets
Patient services	$	675	$	621
Dispensary	—		—
Clinical trials & other	52		53
Total segment amortization	$	727	$	674
Operating income
Patient services	$	6,378	$	6,808
Dispensary	5,079		3,355
Clinical trials & other	1,493		1,188
Total segment operating income	$	12,950	$	11,351
Goodwill impairment charges
Patient services	$	16,235	$	—
Dispensary	—		—
Clinical trials & other	632		—
Total impairment charges	$	16,867	$	—
Selling, general and administrative expense	$	28,830	$	29,806
Non-segment depreciation and amortization	120		16
Total consolidated operating loss	$	(32,867)	$	(18,471)

(in thousands)	March 31, 2023		December 31, 2022
Assets
Patient services	$	70,241	$	64,869
Dispensary	9,872		7,194
Clinical trials & other	11,471		11,496
Non-segment assets	143,049		178,106
Total assets	$	234,633	$	261,665